Trade Vir Biotechnology ^VIR

Vir Biotechnology (NASDAQ:VIR) Posts Earnings Results, Beats Expectations By $0.11 EPS - Stock Observer

A Look At Vir Biotechnology (VIR) Valuation After Astellas Collaboration On VIR-5500 And Early Phase 1 Update

Insider Selling: Vir Biotechnology (NASDAQ:VIR) CEO Sells 19,039 Shares of Stock

Insider Selling: Vir Biotechnology (NASDAQ:VIR) CAO Sells 1,829 Shares of Stock

Insider Selling: Vir Biotechnology (NASDAQ:VIR) CFO Sells 2,089 Shares of Stock

Insider Selling: Vir Biotechnology (NASDAQ:VIR) EVP Sells 2,089 Shares of Stock

Verneuil Vanina De Sells 4,445 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Assessing Vir Biotechnology (VIR) Valuation After A Strong Year To Date Share Price Rebound

Vir Biotechnology (NASDAQ:VIR) CEO Sells $141,840.55 in Stock - Stock Observer

5 Stocks I'm Buying While the Crowd Focuses on AI Disaster - TheStreet Pro

Anthropic expands Claude AI chatbot, Keurig Dr Pepper's Q4 beat

Vir Biotechnology (NASDAQ:VIR) Hits New 52-Week High After Earnings Beat

Promising Small Cap Stocks To Follow Now - February 24th - Stock Observer

Vir Biotech Soars On Global Collaboration With Astellas, Encouraging Prostate Cancer Drug Data

Vir Biotechnology Shares Jump Over 50% After Positive Phase 1 VIR-5500 Prostate Cancer Data

Vir Biotechnology Inc (VIR) Q4 2025 Earnings Call Highlights: Strategic Collaborations and ...

Vir Biotechnology (NASDAQ:VIR) Releases Earnings Results, Beats Expectations By $0.11 EPS

Vir Biotechnology Q4 Earnings Call Highlights - Stock Observer

Japan's Astellas announces $1.37 B deal with Vir Biotechnology to develop T-Cell therapies for prostate cancer

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results | Morningstar

Astellas and Vir Biotechnology Announce Global Strategic Col

Astellas collaborates with Vir to develop its experimental prostate cancer drug

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer | Morningstar

Vir Biotechnology (NASDAQ:VIR) CAO Sells $11,918.70 in Stock

Aberdeen Group plc Purchases 519,374 Shares of Vir Biotechnology, Inc. $VIR

Vir Biotechnology (NASDAQ:VIR) CAO Brent Sabatini Sells 1,530 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of "Moderate Buy" by Analysts

Vir Biotechnology (VIR) Projected to Post Earnings on Monday

Needham & Company LLC Reiterates Buy Rating for Vir Biotechnology (NASDAQ:VIR) - Markets Daily

Vir Biotechnology (NASDAQ:VIR) Earns Buy Rating from Needham & Company LLC - Stock Observer

Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares

Did Vir's Advancing Hepatitis D Combo Program Just Shift Vir Biotechnology's (VIR) Investment Narrative? - Simply Wall St News

Chronic Hepatitis D Market Poised for Significant Growth During the Forecast Period (2025-2034) as Emerging Therapies Drive Optimism | DelveInsight

US Economy on Stagflation Watch: Apollo Global Management's Outlook

AI Podcast: Fresh Insights on Fed Rate Cut Timing - News in a New Way

S&P 500 Earnings Season to Test Rally Amidst Dim Outlook

AI Podcast: Stock Market Melt-Up Potential? Examining the Bull Run

AI Podcast: Does the Gold-Platinum Ratio Signal Stock Market Risk?

Trump's Sudden Russia Policy Shift: Rubio's Influence and Implications

Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty

September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations

Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge

Fund Managers Cautious in Q4: AI, Inflation, and Monetary Policy in Focus

US Government Shutdown Threatens October Inflation Data Release

US-EU Relations: Russia Sanctions Unite Despite Trade Tensions

BOJ Warns of Japan Stock Market Overheating, U.S. Trade Policy Risk